FTC puts conditions on Akorn’s proposed purchase of Hi-Tech Pharmacal
MLex Summary: Pharmaceutical company Akorn and its Nasdaq-listed rival Hi-Tech Pharmacal will sell the rights and assets to three generic prescription eye medications and two topical anesthetics to Watson Laboratories. The divestiture will settle the...To view the full article, register now.
Already a subscriber? Click here to view full article